PTGX [NASD]
Protagonist Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own1.70% Shs Outstand48.75M Perf Week0.13%
Market Cap375.24M Forward P/E- EPS next Y-3.64 Insider Trans-1.81% Shs Float47.96M Perf Month-16.47%
Income-122.50M PEG- EPS next Q-0.93 Inst Own- Short Float6.97% Perf Quarter-67.59%
Sales46.90M P/S8.00 EPS this Y-40.90% Inst Trans2.50% Short Ratio2.86 Perf Half Y-77.34%
Book/sh6.19 P/B1.27 EPS next Y-17.00% ROA-33.30% Target Price43.57 Perf Year-77.48%
Cash/sh6.40 P/C1.23 EPS next 5Y- ROE-38.00% 52W Range7.39 - 50.54 Perf YTD-77.02%
Dividend- P/FCF- EPS past 5Y-1.00% ROI-41.90% 52W High-84.45% Beta2.59
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low6.36% ATR0.95
Employees122 Current Ratio7.90 Sales Q/Q314.50% Oper. Margin- RSI (14)24.97 Volatility5.15% 7.98%
OptionableYes Debt/Eq0.00 EPS Q/Q20.90% Profit Margin- Rel Volume0.81 Prev Close7.70
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume1.17M Price7.86
Recom1.60 SMA20-10.27% SMA50-55.01% SMA200-72.76% Volume943,290 Change2.08%
Feb-11-22Initiated BTIG Research Buy $55
Oct-12-21Upgrade JP Morgan Neutral → Overweight $49 → $55
Oct-11-21Upgrade Northland Capital Market Perform → Outperform $40
Sep-20-21Downgrade JP Morgan Overweight → Neutral $60 → $49
May-24-21Initiated Northland Capital Outperform $42
May-24-21Initiated JMP Securities Mkt Outperform $48
Jan-06-21Initiated JP Morgan Overweight
Dec-16-20Initiated Piper Sandler Overweight $53
Sep-18-20Reiterated H.C. Wainwright Buy $28 → $33
Jul-15-20Initiated Jefferies Buy $27
May-18-20Reiterated H.C. Wainwright Buy $23 → $28
Jul-08-19Initiated H.C. Wainwright Buy $23
May-09-19Upgrade Stifel Hold → Buy $11 → $17
Dec-06-18Initiated Nomura Buy $13
Jan-29-18Initiated Stifel Buy $32
Jul-21-17Initiated BTIG Research Buy $36
May-11-22 08:13AM  
06:16AM  
May-04-22 06:35PM  
04:05PM  
01:29PM  
Apr-27-22 12:44PM  
Apr-26-22 08:38AM  
Apr-25-22 04:25PM  
Apr-19-22 04:15PM  
Apr-14-22 05:44PM  
04:17PM  
08:27AM  
06:31AM  
Mar-28-22 07:06AM  
Mar-16-22 07:00AM  
Feb-28-22 06:15PM  
04:05PM  
Feb-24-22 05:40PM  
Feb-16-22 10:39AM  
05:26AM  
Feb-10-22 07:00AM  
Feb-07-22 12:44PM  
Jan-19-22 04:30AM  
Jan-12-22 11:26AM  
Jan-04-22 12:24PM  
Dec-23-21 12:38PM  
Dec-12-21 09:30AM  
Dec-03-21 07:00AM  
Dec-02-21 04:05PM  
Nov-15-21 07:00AM  
Nov-11-21 07:00AM  
Nov-08-21 08:12AM  
Nov-04-21 07:00AM  
Nov-03-21 06:25PM  
04:05PM  
Oct-27-21 03:03PM  
Oct-26-21 07:00AM  
Oct-18-21 06:09AM  
Oct-14-21 09:27AM  
Oct-13-21 08:25PM  
Oct-12-21 07:00AM  
05:01AM  
Oct-11-21 04:07PM  
12:04PM  
08:11AM  
07:00AM  
Oct-04-21 07:00AM  
Sep-23-21 11:00AM  
Sep-22-21 09:11PM  
11:40AM  
07:59AM  
Sep-21-21 02:58PM  
Sep-20-21 04:14PM  
Sep-17-21 04:06PM  
03:10PM  
02:48PM  
12:12PM  
07:00AM  
Sep-15-21 05:05PM  
Sep-07-21 07:00AM  
Aug-10-21 08:05AM  
01:53AM  
Aug-04-21 06:45PM  
04:05PM  
Jul-29-21 03:05PM  
Jul-28-21 04:05PM  
Jul-21-21 04:32AM  
Jul-06-21 07:17AM  
Jun-30-21 04:27PM  
Jun-18-21 04:05PM  
Jun-17-21 08:57AM  
Jun-16-21 06:53AM  
Jun-15-21 09:07PM  
Jun-14-21 05:00PM  
09:38AM  
Jun-11-21 02:09PM  
07:00AM  
Jun-07-21 07:06AM  
Jun-03-21 07:00AM  
May-24-21 07:00AM  
May-21-21 10:59AM  
May-12-21 11:14AM  
May-04-21 06:20PM  
04:01PM  
May-03-21 05:47PM  
Apr-27-21 07:00AM  
Apr-24-21 05:08PM  
Apr-07-21 08:47AM  
Mar-22-21 04:01PM  
08:03AM  
Mar-10-21 05:55PM  
04:01PM  
01:30PM  
Mar-03-21 07:00AM  
Mar-02-21 12:30PM  
07:00AM  
Feb-26-21 06:19PM  
Feb-16-21 07:00AM  
Jan-29-21 06:22PM  
Jan-07-21 04:18AM  
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PATEL DINESH V PH DPresident and CEOMay 04Option Exercise4.2115,74266,274584,048May 04 08:33 PM
Waddill William D.DirectorMay 03Option Exercise8.5912,000103,08012,000May 04 08:41 PM
Gupta SuneelChief Development OfficerApr 26Option Exercise7.3840,000295,200117,561Apr 26 09:42 PM
PATEL DINESH V PH DPresident and CEOApr 26Option Exercise4.2130,000126,300568,306Apr 26 09:34 PM
PATEL DINESH V PH DPresident and CEOApr 14Option Exercise1.8934,08764,424537,847Apr 14 08:09 PM
PATEL DINESH V PH DPresident and CEODec 21Sale32.1415,000482,170477,158Dec 23 04:17 PM
PATEL DINESH V PH DPresident and CEOSep 21Option Exercise4.2140,000168,400492,158Sep 21 09:45 PM
Liu David YChief Scientific OfficerAug 17Option Exercise0.8710,0008,70073,033Aug 19 05:49 PM
Liu David YChief Scientific OfficerAug 17Sale47.5614,779702,88958,254Aug 19 05:49 PM